REG - Hikma Pharmaceutical - Director/PDMR Shareholding <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

17/03/2016 15:52

RNS Number : 4832S
Hikma Pharmaceuticals Plc
17 March 2016
Hikma Pharmaceuticals PLC - EIP Awards
LONDON, 17 March 2016: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the Remuneration Committee has made the following conditional awards under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.
Awards under the EIP were made on 17 March 2016 at a price of 1,815 pence per Ordinary Share (being the closing price the day before grant) as follows:
PDMR
Element B
Shares
Element C
Shares
Said Darwazah
68,346
45,100
Mazen Darwazah
38,501
25,406
Bassam Kanaan
26,090
26,090
Majda Labadi
14,530
14,530
Riad Mishlawi
19,890
19,890
Khalid Nabulsi
20,400
20,400
Mike Raya
29,484
29,484
Susan Ringdal
15,730
15,730
The Element B share awards will be released to the participants in two years from the date of grant subject to their continued employment and the non-occurrence of forfeiture events during the vesting period as judged by the Remuneration Committee at each anniversary of the grant.
The Element C share awards will be released to the participants in three years from the date of grant subject to their continued employment.
These participants are must retain 50% of the vested shares under elements B and C until five years from the date of grant.
Further details on the EIP, forfeiture criteria and holding period can be found in Hikma's report and accounts for the year ended 31 December 2014 on pages 98, 103 and 104. 
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC 
Peter Speirs   +44 20 7399 2760
Company Secretary
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RDSBUGDXXDBBGLR